Researchers at Duke-NUS Medical School have identified a molecular switch controlled by the protein GATA6 that determines whether pancreatic cancer cells respond to chemotherapy or become resistant.

Almac licenses the Rosetta Resolver® system for use in the development of microarray-based approaches for diagnosing cancer. with the Breaking Science News daily newsletter ...